Feasibility and cost of treatment with drug eluting stents of surgical candidates with multi-vessel coronary disease

European Journal of Cardio-thoracic Surgery

Volumn 26, Issue 3, 2004, Pages 528-534

  Griffiths, Huw ^a   Bakhai, Ameet ^a   West, Douglas ^a   Petrou, Mario ^a   De Souza, Tony ^a   Moat, Neil ^a   Pepper, John ^a   Di Mario, Carlo ^a  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Coronary bypass grafting; Cost; Drug eluting stents; Percutaneous coronary intervention

Indexed keywords

RAPAMYCIN;

AGED; ANASTOMOSIS; ANGIOCARDIOGRAPHY; ARTERY GRAFT; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; COST BENEFIT ANALYSIS; COST CONTROL; DIABETES MELLITUS; DRUG COST; DRUG ELUTING STENT; FEASIBILITY STUDY; FEMALE; HEALTH CARE COST; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE; TREATMENT CONTRAINDICATION;

AGED; BLOOD VESSEL PROSTHESIS IMPLANTATION; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DRUG IMPLANTS; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; RETROSPECTIVE STUDIES; STENTS;

EID: 4143135288     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2004.05.018     Document Type: Conference Paper

References (23)

1. Morice M.C., Serruys P.W., Sousa J.E., Fajadet J., Ban Hayashi E., Perin M., Colombo A., Schuler G., Barragan P., Guagliumi G., Molnar F., Falotico R., RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 346:2002;1773-1780
2. Holmes D.R. Jr, Leon M.B., Moses J.W., Popma J.J., Cutlip D., Fitzgerald P.J., Brown C., Fischell T., Wong S.C., Midei M., Snead D., Kuntz R.E., on behalf of the SIRIUS Trial Investigators. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomised trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. 109:(5):2004;634-640
3. Serruys P.W., Unger F., Sousa J.E., Jatene A., Bonnier H.J., Schonberger J.P., Buller N., Bonser R., van den Brand M.J., van Herwerden L.A., Morel M.A., van Hout B.A. Comparison of coronary artery bypass surgery and stenting for the treatment of multi-vessel disease. N Engl J Med. 344:2001;1117-1124
4. Sigwart U., Stables R.H., Booth J., Erbel R., Wahrborg P., Lubsen J., Nihoyannopoulos P., Pepper J., King S.B. III, Weintraub W., Sleight P., on behalf of the SoS Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multi-vessel coronary artery disease (the Stent or Surgery Trial): a randomised controlled trial. Lancet. 360:2002;965-970
5. Olivari Z., Rubartelli P., Piscione F., Ettori F., Fontanelli A., Salemme L., Giachero C., Di Mario C., Gabrielli G., Spedicato L., Bedogni F., on behalf of the TOAST-GISE Investigators. Immediate results and one-year clinical outcome after percutaneous coronary interventions in chronic total occlusions: data from a multi-center, prospective, observational study (TOAST-GISE). J Am Coll Cardiol. 41:(10):2003;1672-1678
6. van Hout B.A., Lindeboom W.K., Morice M.C., de Jong P., Molnar F., Wijns W., Holubarsch C., Bartorelli A., on behalf of the RAVEL Investigators. Cost-effectiveness of the sirolimus eluting Bx-VELOCITY stent: 1-year results (Abstract). Eur Heart J. 23:(Abstr. Suppl.):2002;691
7. Hampton J.R., Henderson R.A., Julian D.G., Parker J., Pocock S.J., Sowton E., Wallwork J., on behalf of RITA trial participants. Coronary angioplasty versus coronary artery bypass surgery: the randomised interventional treatment of angina (RITA) trial. Lancet. 341:1993;573-580
8. Rodriguez A., Boullon F., Perez-Balino N., Paviotti C., Liprandi M.I., Palacios I.F., on behalf of the ERACI group. Argentine randomised trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multi-vessel disease (ERACI): in hospital results and 1 year follow up. J Am Coll Cardiol. 22:1993;1060-1067
9. King S.B.I.I.I., Lembo N.J., Weintraub W.S., Kosinski A.S., Barnhart H.X., Kutner M.H., Alazraki N.P., Guyton R.A., Zhao X.O., for the Emory Angioplasty versus Surgery Trial (EAST). A randomised trial comparing coronary angioplasty with coronary bypass surgery. N Engl J Med. 331:1994;1044-1050
10. Rickards A.F., Ilsley C., Simon R., Probst R., Danchin N., Bowker T., on behalf of CABRI trial participants. First year results of CABRI (Coronary Angioplasty versus Bypass Surgery Investigation). Lancet. 346:1995;1179-1184
11. Alderman E.L., Andrews K., Bost J., Bourassa M., Chaitman B.R., Detre K., Faxon D.P., Follmann D., Frye R.L., Hlatky M., Jones R.H., Kelsey S.F., Rogers W.J., Rosen A.D., Schaff H., Sellers M.A., Sopks G., Tyrrell K.S., Williams D.O., on behalf of the BARI Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multi-vessel disease. N Engl J Med. 335:1996;217-225
12. Rodriguez A., Bernardi V., Navia J., Baldi J., Grinfeld L., Martinez J., Vogel D., Grinfeld R., Delacasa A., Garrido M., Oliveri R., Mele E., Palacios I., O'Neill W., on behalf of the ERACI II Investigators. Argentine randomised study: coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II): 30 Day and one year follow up results. J Am Coll Cardiol. 37:2001;51-58
13. Morice M.C., Serruys P., Costantino C., Wuelfert E., Wijns W., Fajadet J., Colombo A., Guagliumi G., Molnar F., Hayashi E.B., Sousa J.E., Perin M., on behalf of the RAVEL Trial Investigators. Two-year follow-up of the RAVEL Study: a randomized study with the sirolimus-eluting Bx VELOCITY stent in the treatment of patients with de novo native coronary artery lesions (Abstract). J Am Coll Cardiol. 41:2003;32A
14. Silvestri M., Barragan P., Sainsous J., Bayet G., Simeoni J.B., Roquebert P.O., Macaluso G., Bouvier J.L., Comet B. Unprotected left main coronary artery stenting: immediate and medium term outcomes of 140 elective procedures. J Am Coll Cardiol. 35:2000;1543-1550
15. Black A., Cortina R., Bossi I., Choussat R., Fajadet J., Marco J. Unprotected left main coronary artery stenting. Correlates of midterm survival and impact of patient selection. J Am Coll Cardiol. 37:2001;832-838
16. Takagi T., Stankovic G., Finci L., Toutouzas K., Chieffo A., Spanos V., Liistro F., Briguori C., Corvaja N., Albero R., Sivieri G., Paloschi R., Di Mario C., Colombo A. Results and long-term predictors of adverse clinical events after elective percutaneous interventions on unprotected left main coronary artery. Circulation. 106:2002;698-702
17. Park S.J., Park S.W., Hong M.K., Lee C.W., Lee J.H., Kim J.J., Jang Y.S., Shin E.K., Yoshida Y., Tamura T., Kimura T., Nobuyoshi M. Long-term (three-year) outcomes after stenting of unprotected left main coronary artery stenosis in patients with normal left ventricular function. Am J Cardiol. 91:2003;12-16
18. Cervinka P., Foley D., Sabate M., Costa M.A., Serrano P., Ligthart J.M., Serruys P.W. Coronary bifurcation stenting using dedicated bifurcation stents. Cath Cardiovasc Intervent. 49:2000;105-111
19. Colombo A., Louvard Y., Raghu C., Di Mario C., Ludwig J., Leon M., Moses J., Morice M.C., Wulfert E., Holmes D. Sirolimus eluting stents in bifurcation lesions: 6 months angiographic result according to the implantation technique (Abstract). J Am Coll Cardiol. 41:2003;53A
20. Cohen D.J., Bakhai A., Shi C., Githiora L., Berezin R.H., Caputo R.P., O'Shaughnessy C., Leon M.B., Moses J., Kuntz R.E., on behalf of the SIRIUS Investigators. Cost-effectiveness of sirolimus drug-eluting stents for the treatment of complex coronary stenoses: Results from the randomized SIRIUS trial (Abstract). J Am Coll Cardiol. 41:2003;32A
21. Legrand V., Serruys P.W., Unger F., Bilodeau L., Carrier M., Mendiz O., Lindeboom W.K., Otto-Terlouw P.C., on behalf of the ARTS. Arterial revascularisation therapy study: a randomised trial of stenting in multi-vessel coronary disease versus bypass surgery. 3 year results (Abstract). Eur Heart J. 23:(Abstr. Suppl.):2002;263
22. Leon M.B., Holmes D.R., Simonton C., Moses J.W., O'Shaughnessy C., Caputo R.P., Wong S.C., Buchbinder M., Chapman G., Kuntz R.E. The impact of sirolimus-eluting stents in diabetics: results from the SIRIUS Trial (Abstract). J Am Coll Cardiol. 41:2003;54A
23. Lemos P.A., Serruys P.W., van Domburg R.T., Saia F., Arampatzis C.A., Hoye A., Degertekin M., Tanabe K., Daemen J., Liu T.K., McFadden E., Sianos G., Hofma S.H., Smits P.C., van der Giessen W.J., de Feyter P.J. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the real world. The rapamycin-eluting stent evaluated at Rotterdam cardiology hospital (RESEARCH) registry. Circulation. 109:(2):2004;190-195